within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX07_Cabozantinib;

model Cabozantinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.34,
    Cl = 6.222222222222223e-07,
    adminDuration = 600,
    adminMass = 60 / 1000000,
    adminCount = 1,
    Vd = 0.349,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0007166666666666666,
    Tlag = 60,
    Vdp = 1.324,
    k12 = 6.805555555555556e-06,
    k21 = 6.805555555555556e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cabozantinib</td></tr><tr><td>ATC code:</td><td>L01EX07</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>60</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>349</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.24</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cabozantinib is an oral multi-kinase inhibitor that targets MET, VEGFR, and other tyrosine kinases. It is approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with advanced solid tumors. Parameters from population pharmacokinetic analyses in clinical studies involving both male and female patients.</p><h4>References</h4><ol><li><p>Miles, D, et al., &amp; Nguyen, L (2016). Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis. <i>Clinical pharmacokinetics</i> 55(1) 93–105. DOI:<a href=\"https://doi.org/10.1007/s40262-015-0295-x\">10.1007/s40262-015-0295-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26149244/\">https://pubmed.ncbi.nlm.nih.gov/26149244</a></p></li><li><p>Castellano, D, et al., &amp; Jonasch, E (2020). Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. <i>Cancer treatment reviews</i> 89 102062–None. DOI:<a href=\"https://doi.org/10.1016/j.ctrv.2020.102062\">10.1016/j.ctrv.2020.102062</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32659623/\">https://pubmed.ncbi.nlm.nih.gov/32659623</a></p></li><li><p>Tran, BD, et al., &amp; Roskos, L (2023). Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma. <i>Cancer chemotherapy and pharmacology</i> 91(2) 179–189. DOI:<a href=\"https://doi.org/10.1007/s00280-022-04500-9\">10.1007/s00280-022-04500-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36625894/\">https://pubmed.ncbi.nlm.nih.gov/36625894</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01EX07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cabozantinib;
